The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! About 133,114 shares traded hands. Genocea Biosciences Inc (NASDAQ:GNCA) has declined 24.83% since April 18, 2016 and is downtrending. It has underperformed by 29.26% the S&P500.
The move comes after 9 months negative chart setup for the $114.63M company. It was reported on Nov, 18 by Barchart.com. We have $3.54 PT which if reached, will make NASDAQ:GNCA worth $16.05 million less.
Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage
Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Needham on Tuesday, October 20. FBR Capital maintained the stock with “Outperform” rating in Monday, October 19 report. The firm has “Buy” rating by Needham given on Tuesday, August 11. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) has “Overweight” rating given on Thursday, August 6 by Piper Jaffray. On Thursday, December 17 the stock rating was initiated by UBS with “Buy”. The firm earned “Buy” rating on Thursday, September 29 by Needham. PiperJaffray maintained the shares of GNCA in a report on Thursday, September 29 with “Overweight” rating.
According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”
More notable recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on February 05, 2014, also Fool.com with their article: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.” published on April 01, 2016, Fool.com published: “Why Genocea Biosciences Inc Stock Dropped Today” on July 30, 2015. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) were released by: 247Wallst.com and their article: “Genocea Biosciences Rises on Positive Herpes Trial Results” published on October 29, 2016 as well as Streetinsider.com‘s news article titled: “Genocea Biosciences (GNCA) Presents New Findings Supporting Potential of ATLAS” with publication date: November 11, 2016.
GNCA Company Profile
Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.